It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Genmab ADR (GMAB) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.08, or 0.25%, to $32.23. The Genmab ADR has recorded 101,434 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Major Shareholder Announcement.
Genmab ADR is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $32.15 and fluctuated between $32.42 as its day high and $31.91 as its day low. The current market capitalization of Genmab ADR is $21.00B. A total of 1.37 million shares were traded on the day, compared to an average of 736.90K shares.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for GMAB in the last 3 months, the mean price target is $41.30 with high estimates of $54.00 and low estimates of $28.77. In terms of 52-week highs and lows, GMAB has a high of $47.50 and a low of $27.74.
As of this writing, GMAB has an earnings estimate of $3.08 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $3.39 per share and a lower estimate of $2.61. The company reported an EPS of $0.3 in the last quarter, which was -86.20% lower than expectations of $2.18.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. GMAB’s latest balance sheet shows that the firm has $19.34B in Cash & Short Term Investments as of fiscal 2021. There were $425.00M in debt and $1.57B in liabilities at the time. Its Book Value Per Share was $6.76, while its Total Shareholder’s Equity was $22.20B.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GMAB is Buy with a score of 3.50.